In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Berlin: Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of aflibercept 8 mg (114.3 ...

Purpose: This study aimed to evaluate the efficacy and safety of intravitreal injection of aflibercept biosimilar in the treatment of diabetic macular edema (DME). Methods: Clinical data were ...

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

Data indicates that the therapy resulted in visual acuity gains and “achieved” non-inferiority to aflibercept at most time points through a 36-week period. The trial included 52 participants who were ...

A failed clinical trial has rattled investors. The post Amid fears of collapse, what's happening with Opthea ASX shares today? appeared first on The Motley Fool Australia.

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from ...